Abstract: Provided are methods of treating cancer using adoptive cell therapy with T cells modified to have a reduced T cell receptor (TCR) signaling threshold and/or increased TCR sensitivity, and to have improved anti-tumor properties, such as increased cytotoxic activity and reduced susceptibility to immune suppression and/or exhaustion. Also provided are methods of making and compositions comprising such modified T cells.